Literature DB >> 29791233

Association of a Chromosome Locus 9p21.3 CDKN2B-AS1 Variant rs4977574 with Hypertension: The TAMRISK Study.

Tarja Kunnas1,2, Jaakko Piesanen1,2, Seppo T Nikkari1,2.   

Abstract

AIMS: Chromosome locus 9p21.3 CDKN2B antisense RNA 1 (CDKN2B-AS1) has been found to contain multiple genetic markers for coronary artery disease (CAD) by genome-wide association studies (GWAS). Of these, the association of variants rs4977574, rs10757274, and rs2383206 with hypertension was studied in the Tampere adult population cardiovascular risk study (TAMRISK).
MATERIALS AND METHODS: A Finnish cohort of 336 subjects diagnosed with hypertension and 444 controls was analyzed. Samples were genotyped for the CDKN2B-AS1 polymorphisms using Kompetitive Allele Specific PCR (KASP) or TaqMan techniques.
RESULTS: Individuals with the minor genotype GG of rs4977574 had less hypertension compared to the other genotypes (p = 0.048, OR 1.58, 95% CI 1.01-2.48). The variants rs2383206 and rs10757274 were not associated with hypertension.
CONCLUSIONS: Our findings suggest that the GG genotype of the CDKN2B-AS1 gene variant rs4977574, which has been previously associated with an increased CAD risk, is also associated with a decreased susceptibility to the development of hypertension.

Entities:  

Keywords:  CDKN2A/B; CDKN2B-AS1; chromosome 9p21.3; genetic variation; hypertension

Mesh:

Substances:

Year:  2018        PMID: 29791233     DOI: 10.1089/gtmb.2017.0249

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  8 in total

1.  Hypertension and the roles of the 9p21.3 risk locus: Classic findings and new association data.

Authors:  Juan E Gallo; Juan E Ochoa; Helen R Warren; Elizabeth Misas; Monica M Correa; Jaime A Gallo-Villegas; Gabriel Bedoya; Dagnóvar Aristizábal; Juan G McEwen; Mark J Caulfield; Gianfranco Parati; Oliver K Clay
Journal:  Int J Cardiol Hypertens       Date:  2020-09-15

2.  Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.

Authors:  Maha Meshal AlRasheed
Journal:  Saudi Pharm J       Date:  2018-07-20       Impact factor: 4.330

3.  Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.

Authors:  Haocheng Li; Song Han; Qingfeng Sun; Ye Yao; Shiyong Li; Chao Yuan; Bo Zhang; Bao Jing; Jia Wu; Ye Song; Haiyang Wang
Journal:  Aging (Albany NY)       Date:  2019-03-29       Impact factor: 5.682

4.  Association between lncRNA ANRIL genetic variants with the susceptibility to ischemic stroke: From a case-control study to meta-analysis.

Authors:  Qianwen Wang; Jingjing Zhao; Hongtao Chang; Xu Liu; Ruixia Zhu
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

5.  The Link between ANRIL Gene RS4977574 Polymorphism and Common Atherosclerosis Cardiovascular Complications: A Hospital-Based Case-Control Study in Ukrainian Population.

Authors:  Polina V Kniazkova; Viktoriia Yu Harbuzova; Vladyslav V Pokhmura
Journal:  Biomed Res Int       Date:  2022-10-05       Impact factor: 3.246

6.  Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter.

Authors:  Minghui Ou; Xia Li; Shibo Zhao; Shichao Cui; Jie Tu
Journal:  EBioMedicine       Date:  2020-04-24       Impact factor: 8.143

7.  Effects of CDKN2B-AS1 polymorphisms on the susceptibility to coronary heart disease.

Authors:  Kang Huang; Jianghua Zhong; Qiang Li; Wei Zhang; Zibin Chen; Yilei Zhou; Miao Wu; Zanrui Zhong; Shijuan Lu; Shufang Zhang
Journal:  Mol Genet Genomic Med       Date:  2019-09-08       Impact factor: 2.183

8.  The lncRNA ANRIL Gene rs2151280 GG Genotype is Associated with Increased Susceptibility to Recurrent Miscarriage in a Southern Chinese Population.

Authors:  Di Che; Zhenzhen Fang; Hanran Mai; Yufen Xu; LanYan Fu; Huazhong Zhou; Linyuan Zhang; Lei Pi; Xiaoqiong Gu
Journal:  J Inflamm Res       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.